Table 2 GO and KEGG pathway enrichment analysis of AAGs in lung adenocarcinoma
Terms | Pathway ID | Pathway description | GeneID | Count | FDR |
|---|---|---|---|---|---|
BP | GO:0050873 | Brown fat cell differentiation | BNIP3/ERO1A | 2 | 0.04082 |
GO:0010660 | Regulation of muscle cell apoptotic process | BNIP3/IFNG/CDKN2A | 3 | 0.02240 | |
GO:0097193 | Intrinsic apoptotic signaling pathway | DAPK2/PPP1R15A/PARP1/P4HB/IKBKE/BNIP3/ERO1A | 7 | 0.00011 | |
GO:0001953 | Negative regulation of cell–matrix adhesion | DLC1/CDKN2A | 2 | 0.04082 | |
GO:0052548 | Regulation of endopeptidase activity | DLC1/NLRC4/GAPDH/BIRC5 | 4 | 0.04616 | |
GO:0052547 | Regulation of peptidase activity | DLC1/NLRC4/GAPDH/BIRC5 | 4 | 0.04990 | |
GO:0034599 | Cellular response to oxidative stress | FOS/PARP1/P4HB/BNIP3/ERO1A | 5 | 0.00916 | |
GO:0061919 | Process utilizing autophagic mechanism | HSPB8/DAPK2/MAP1LC3C/BNIP3/IFNG/VMP1/ITGB4/GAPDH/ATG9B/TMEM74 | 10 | 0.00000 | |
GO:0016236 | Macroautophagy | HSPB8/MAP1LC3C/BNIP3/VMP1/GAPDH/ATG9B/TMEM74 | 7 | 0.00011 | |
GO:0035967 | Cellular response to topologically incorrect protein | HSPB8/PPP1R15A/CCL2/HSPA5/ERO1A | 5 | 0.00066 | |
GO:0006986 | Response to unfolded protein | HSPB8/PPP1R15A/CCL2/HSPA5/ERO1A | 5 | 0.00118 | |
GO:0001558 | Regulation of cell growth | NRG3/PRKCQ/ERBB2/CDKN2A | 4 | 0.04988 | |
GO:0006575 | Cellular modified amino acid metabolic process | P4HB/ATIC/ERO1A | 3 | 0.04632 | |
GO:0071456 | Cellulaar response to hypoxia | P4HB/BNIP3/EIF4EBP1/ERO1A | 4 | 0.01895 | |
GO:0019471 | 4-hydroxyproline metabolic process | P4HB/ERO1A | 2 | 0.00966 | |
GO:0030968 | Endoplasmic reticulum unfolded protein response | PPP1R15A/CCL2/HSPA5/ERO1A | 4 | 0.00411 | |
GO:0034976 | Response to endoplasmic reticulum stress | PPP1R15A/CCL2/HSPA5/P4HB/ERO1A | 5 | 0.00551 | |
GO:0070059 | Intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | PPP1R15A/ERO1A | 2 | 0.04990 | |
CC | GO:0005776 | Autophagosome | DAPK2/MAP1LC3C/VMP1/ATG9B/TMEM74 | 5 | 0.00001 |
GO:0000421 | Autophagosome membrane | MAP1LC3C/VMP1/ATG9B/TMEM74 | 4 | 0.00001 | |
MF | GO:0019887 | Protein kinase regulator activity | NRG3/NRG1/CDKN2A | 3 | 0.03024 |
KEGG Pathways | hsa04140 | Autophagy-animal | VMP1/DAPK2/BNIP3/ATG9B/PRKCQ | 5 | 0.00940 |
hsa04012 | ErbB signaling pathway | NRG1/ERBB2/NLRC4/EIF4EBP1 | 4 | 0.01011 | |
hsa04657 | IL-17 signaling pathway | CCL2/IFNG/ITGB4/FOS | 4 | 0.01011 | |
hsa05219 | Bladder cancer | DAPK2/CDKN2A/ERBB2 | 3 | 0.01028 | |
hsa04066 | HIF-1 signaling pathway | IFNG/ERO1A/GAPDH/EIF4EBP1 | 4 | 0.01071 | |
hsa05323 | Rheumatoid arthritis | CCL2/ITGB4/FOS | 3 | 0.03726 | |
hsa01524 | Platinum drug resistance | BIRC5/CDKN2A/ERBB2 | 3 | 0.03236 | |
hsa04141 | Protein processing in endoplasmic reticulum | ERO1A/P4HB/PPP1R15A/HSPA5 | 4 | 0.03236 | |
hsa01521 | EGFR tyrosine kinase inhibitor resistance | NRG1/ERO1A/EIF4EBP1 | 3 | 0.03236 | |
hsa05132 | Salmonella infection | NLRC4/IFNG/FOS | 3 | 0.03236 | |
hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | IFNG/FOS/CDKN2A | 3 | 0.03726 | |
hsa01522 | Endocrine resistance | CDKN2A/FOS/ERBB2 | 3 | 0.03988 | |
hsa05142 | Chagas disease (American trypanosomiasis) | CCL2/IFNG/FOS | 3 | 0.04085 | |
hsa04660 | T cell receptor signaling pathway | IFNG/FOS/NLRC4 | 3 | 0.04085 | |
hsa04659 | Th17 cell differentiation | IFNG/PRKCQ/NLRC4 | 3 | 0.04147 |